preview

oral chemo 1

explanatory Essay
878 words
878 words
bookmark

The Leukemia and Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer (Leukemia & Lymphoma Society, n.d.). Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada(Leukemia & Lymphoma Society, n.d.). The LLS mission is to cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care (Leukemia & Lymphoma Society, n.d.). Every 4 minutes, someone is diagnosed with a blood cancer; and every 10 minutes, someone dies of a blood cancer (Leukemia & Lymphoma Society, n.d.). In 2013, over 3,000 Missourians were diagnosed with a blood cancer. The LLS currently has nearly $4 million dollars invested in Missouri to find cancer cures(Leukemia & Lymphoma Society, n.d.). Meg Boyko is the patient access, education and advocacy manager in the St. Louis Gateway Chapter Leukemia & Lymphoma Society and the mentor of the Field Experience Project for this paper. She spends countless hours educating patients, families, communities, and political leaders about blood cancers promoting parity for oral and intravenous chemotherapy treatments. She is a strong advocate who has a way of drawing people in and encouraging them to participate in the LLS mission to cure blood cancers, aid in improving the quality of life of patients and their families. She pulls out the strengths of each advocate, and utilizes them to benefit the needs of those suffering with a blood cancer. The advocates work well together and feel ... ... middle of paper ... ...l cancer medications. It is estimated that as many as ten percent of cancer patients do not fill oral prescriptions and, thus, do not receive their recommended cancer treatment due to high out-of-pocket costs. A 2009 study found that patients with an out-of-pocket cost of greater than $200 per prescription were at least three times less likely to fill their prescription for their oral anti-cancer drugs, compared to patients with out-of-pocket costs of $100 or less. Abandoning one’s medication may lead to costly follow-up visits or hospitalization, among other issues. Equitable access to oral drugs can help prevent this outcome. Lower out-of-pocket costs for patients mean they are more likely to adhere to their anticancer regimen as several studies have shown that the higher the cost-sharing amounts, the less likely patients are to follow through on their treatment.

In this essay, the author

  • Explains that the leukemia and lymphoma society (lls) is the world's largest voluntary health agency dedicated to blood cancer.
  • Describes meg boyko as the patient access, education, and advocacy manager in the st. louis gateway chapter leukemia & lymphoma society and the mentor of the field experience project for this paper.
  • Explains that insurance benefit designs haven't kept pace with advances in oral anti-cancer therapies, which means higher patient cost-sharing obligations.
  • Explains that oral oncology drugs target specific biologic processes in cancer cells and block their growth, and are convenient for patients who live far from a treatment facility.
Get Access